Emilio Alba

List of Publications by Citations

204 papers	6,481 citations	45 h-index	76 g-index
238 ext. papers	7,759 ext. citations	4.8 avg, IF	5.12 L-index

#	Paper	IF	Citations
204	Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. *New England Journal of Medicine*, **2016**, 375, 1738-1748	59.2	975
203	Missing data imputation using statistical and machine learning methods in a real breast cancer problem. *Artificial Intelligence in Medicine*, **2010**, 50, 105-15	7.4	240
202	PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. *BMC Medical Genomics*, **2012**, 5, 44	3.7	199
201	Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. *Journal of the National Cancer Institute*, **2008**, 100, 805-14	9.7	174
200	Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. *British Journal of Cancer*, **2002**, 86, 1367-72	8.7	162
199	Adjuvant docetaxel for high-risk, node-negative breast cancer. *New England Journal of Medicine*, **2010**, 363, 2200-10	59.2	149
198	Seeing topological order in time-of-flight measurements. *Physical Review Letters*, **2011**, 107, 235301	7.4	149
197	A combined neural network and decision trees model for prognosis of breast cancer relapse. *Artificial Intelligence in Medicine*, **2003**, 27, 45-63	7.4	140
196	Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. *Annals of Oncology*, **2015**, 26, 1280-91	10.3	127
195	Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. *Annals of Oncology*, **2012**, 23, 3069-3074	10.3	123
194	Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study. *Journal of Clinical Oncology*, **2004**, 22, 2587-93	2.2	109
193	A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study. *Breast Cancer Research and Treatment*, **2012**, 136, 487-93	4.4	106
192	A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma. *Clinical Cancer Research*, **2008**, 14, 811-6	12.9	104
191	Defining breast cancer intrinsic subtypes by quantitative receptor expression. *Oncologist*, **2015**, 20, 474-82	5.7	102
190	Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. *Lancet Oncology, The*, **2014**, 15, 1351-60	21.7	102
189	Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations. *Oncologist*, **2009**, 14, 1-11	5.7	100
188	Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial. *Breast Cancer Research*, **2014**, 16, R38	8.3	97

187	Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer. *Annals of Oncology*, **2012**, 23, 625-631	10.3	93
186	Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma. *Annals of Oncology*, **2003**, 14, 867-72	10.3	91
185	Predicting response and survival in chemotherapy-treated triple-negative breast cancer. *British Journal of Cancer*, **2014**, 111, 1532-41	8.7	82
184	Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG). *European Urology*, **2002**, 42, 553-62; discussion 562-3	10.2	81
183	Letrozole efficacy is related to human aromatase CYP19 single nucleotide polymorphisms (SNPs) in metastatic breast cancer. *Breast Cancer Research*, **2005**, 7, 1	8.3	78
182	Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy. *Oncotarget*, **2018**, 9, 26406-26416	3.3	76
181	Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index. *Breast Cancer Research*, **2013**, 15, R98	8.3	69
180	Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer. *BioEssays*, **2007**, 29, 1159-68	4.1	69
179	Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. *Lancet Oncology, The*, **2011**, 12, 369-76	21.7	68
178	GLIM Criteria Using Hand Grip Strength Adequately Predict Six-Month Mortality in Cancer Inpatients. *Nutrients*, **2019**, 11,	6.7	64
177	A microRNA signature associated with early recurrence in breast cancer. *PLoS ONE*, **2014**, 9, e91884	3.7	64
176	Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. *Breast Cancer Research and Treatment*, **2010**, 123, 149-57	4.4	63
175	Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study. *Breast Cancer Research and Treatment*, **2010**, 122, 169-76	4.4	61
174	Gemcitabine in combination with doxorubicin in advanced breast cancer: final results of a phase II pharmacokinetic trial. *Journal of Clinical Oncology*, **2000**, 18, 2545-52	2.2	58
173	Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay. *Clinical Cancer Research*, **2016**, 22, 560-6	12.9	57
172	A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression. *Current Drug Metabolism*, **2008**, 9, 336-43	3.5	56
171	Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer. *Clinical and Translational Oncology*, **2008**, 10, 583-6	3.6	56
170	Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study. *Annals of Oncology*, **2004**, 15, 1798-804	10.3	55

169	Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study. *Annals of Oncology*, **2004**, 15, 79-87	10.3	55
168	Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review. *Annals of Oncology*, **2017**, 28, 2943-2949	10.3	51
167	Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis. *Breast Cancer Research*, **2013**, 15, R105	8.3	50
166	Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2. *Breast Cancer Research and Treatment*, **2018**, 170, 535-545	4.4	49
165	Improvement of breast cancer relapse prediction in high risk intervals using artificial neural networks. *Breast Cancer Research and Treatment*, **2005**, 94, 265-72	4.4	49
164	Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial. *British Journal of Cancer*, **2014**, 110, 1139-47	8.7	48
163	A phase II study of concomitant boost radiation plus concurrent weekly cisplatin for locally advanced unresectable head and neck carcinomas. *Radiotherapy and Oncology*, **2006**, 79, 34-8	5.3	46
162	Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial. *Breast Cancer Research and Treatment*, **2018**, 167, 659-669	4.4	45
161	New insights into the role of the immune microenvironment in breast carcinoma. *Clinical and Developmental Immunology*, **2013**, 2013, 785317		45
160	Influence of timing of initiation of adjuvant chemotherapy over survival in breast cancer: a negative outcome study by the Spanish Breast Cancer Research Group (GEICAM). *Breast Cancer Research and Treatment*, **2007**, 101, 215-23	4.4	45
159	21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.. *New England Journal of Medicine*, **2021**, 385, 2336-2347	59.2	45
158	Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer. *BMC Cancer*, **2010**, 10, 136	4.8	44
157	Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. *Oncology*, **2010**, 79, 98-104	3.6	43
156	The seed and soil hypothesis revisited: current state of knowledge of inherited genes on prognosis in breast cancer. *Cancer Treatment Reviews*, **2014**, 40, 293-9	14.4	37
155	Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response. *Journal of Clinical Medicine*, **2020**, 9,	5.1	33
154	Practical prognostic index for patients with metastatic recurrent breast cancer: retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register. *Breast Cancer Research and Treatment*, **2010**, 122, 591-600	4.4	33
153	Maintenance treatment in metastatic breast cancer. *Expert Review of Anticancer Therapy*, **2008**, 8, 1907-12	3.5	33
152	Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications. *Frontiers in Oncology*, **2019**, 9, 1124	5.3	32

151	Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients. *Oral Oncology*, **2013**, 49, 182-5	4.4	31
150	Negative prognostic impact of the coexpression of epidermal growth factor receptor and c-erbB-2 in locally advanced cervical cancer. *Oncology*, **2009**, 76, 133-41	3.6	30
149	Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen. *Oncotarget*, **2016**, 7, 37680-37692	3.3	30
148	First-line ribociclib plus letrozole in postmenopausal women with HR+´, HER2-´advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial. *Breast Cancer Research and Treatment*, **2018**, 169, 469-479	4.4	29
147	BOMP/EPI intensive alternating chemotherapy for IGCCC poor-prognosis germ-cell tumors: the Spanish Germ-Cell Cancer Group experience (GG). *Annals of Oncology*, **1999**, 10, 289-93	10.3	29
146	The functional interaction of 14-3-3 proteins with the ERK1/2 scaffold KSR1 occurs in an isoform-specific manner. *Journal of Biological Chemistry*, **2008**, 283, 17450-62	5.4	28
145	Human pregnane X receptor is expressed in breast carcinomas, potential heterodimers formation between hPXR and RXR-alpha. *BMC Cancer*, **2008**, 8, 174	4.8	27
144	Six cycles of ABVD in the treatment of stage I and II Hodgkin® lymphoma: a pilot study. *Journal of Clinical Oncology*, **1997**, 15, 1118-22	2.2	26
143	Elevated Serum Levels of Vascular Endothelial Growth Factor Are Associated With Tumor-Associated Macrophages in Primary Breast Cancer. *American Journal of Clinical Pathology*, **2006**, 125, 111-118	1.9	26
142	Breast and Gut Microbiota Action Mechanisms in Breast Cancer Pathogenesis and Treatment. *Cancers*, **2020**, 12,	6.6	26
141	Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer. *BMC Cancer*, **2013**, 13, 26	4.8	25
140	F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial. *Clinical Cancer Research*, **2017**, 23, 1432-1441	12.9	25
139	Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations. *Clinical and Translational Oncology*, **2012**, 14, 94-101	3.6	24
138	Anticipatory nausea and vomiting: prevalence and predictors in chemotherapy patients. *Oncology*, **1989**, 46, 26-30	3.6	23
137	Detection of and Mutations in Circulating Tumor DNA Using Next-Generation Sequencing in the Screening Process for Early Breast Cancer Diagnosis. *Journal of Clinical Medicine*, **2019**, 8,	5.1	21
136	Serum protein levels following surgery in breast cancer patients: a protein microarray approach. *International Journal of Oncology*, **2012**, 41, 2200-6	4.4	21
135	High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer. *Oncologist*, **2016**, 21, 150-5	5.7	21
134	Optimizing taxane use in MBC in the emerging era of targeted chemotherapy. *Critical Reviews in Oncology/Hematology*, **2013**, 85, 315-31	7	20

133	Psychological impact of multigene cancer panel testing in patients with a clinical suspicion of hereditary cancer across Spain. *Psycho-Oncology*, **2018**, 27, 1530-1537	3.9	19
132	Adjuvant anthracycline therapy as a prognostic factor in metastatic breast cancer. *Breast Cancer Research and Treatment*, **2001**, 66, 33-9	4.4	18
131	A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse. *Clinical Cancer Research*, **2017**, 23, 3035-3044	12.9	17
130	The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value. *Clinical Breast Cancer*, **2013**, 13, 146-52	3	17
129	Limited impact of palliative chemotherapy on survival in advanced solid tumours in patients with poor performance status. *Clinical and Translational Oncology*, **2011**, 13, 426-9	3.6	17
128	Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in "real world" patients. *Clinical and Translational Oncology*, **2018**, 20, 922-927	3.6	17
127	Addressing critical issues in the development of an Oncology Information System. *International Journal of Medical Informatics*, **2013**, 82, 398-407	5.3	16
126	Erythropoietin pharmacology. *Clinical and Translational Oncology*, **2007**, 9, 715-22	3.6	16
125	Follow-up of breast cancer stages I and II. An analysis of some common methods. *European Journal of Cancer & Clinical Oncology*, **1987**, 23, 419-23		16
124	Prolongation of TTP by maintenance therapy with PLD in a multicenter phase III randomized trial following standard chemotherapy for MBC: GEICAM 2001 01 study. *Journal of Clinical Oncology*, **2007**, 25, 1007-1007	2.2	15
123	Shallow whole genome sequencing for robust copy number profiling of formalin-fixed paraffin-embedded breast cancers. *Experimental and Molecular Pathology*, **2018**, 104, 161-169	4.4	14
122	Outcomes of single versus double hormone receptor-positive breast cancer. A GEICAM/9906 sub-study. *European Journal of Cancer*, **2018**, 94, 199-205	7.5	14
121	Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain. *Expert Review of Pharmacoeconomics and Outcomes Research*, **2013**, 13, 381-91	2.2	14
120	Association between VEGF expression in tumour-associated macrophages and elevated serum VEGF levels in primary colorectal cancer patients. *Cancer Biomarkers*, **2007**, 3, 325-33	3.8	14
119	Validation of the 2001 St Gallen risk categories for node-negative breast cancer using a database from the Spanish Breast Cancer Research Group (GEICAM). *Journal of Clinical Oncology*, **2004**, 22, 961-2	2.2	14
118	Secondary prophylactic G-CSF (filgrastim) administration in chemotherapy of stage I and II Hodgkin's lymphoma with ABVD. *Leukemia and Lymphoma*, **2001**, 41, 353-8	1.9	14
117	Challenges and achievements of liquid biopsy technologies employed in early breast cancer. *EBioMedicine*, **2020**, 62, 103100	8.8	14
116	Elevated vascular endothelial growth factor pretreatment levels are correlated with the tumor burden in Hodgkin lymphoma and continue to be elevated in prolonged complete remission. *Clinical Lymphoma and Myeloma*, **2007**, 7, 400-5		13

115	Serum endostatin and bFGF as predictive factors in advanced breast cancer patients treated with letrozole. *Clinical and Translational Oncology*, **2006**, 8, 193-9	3.6	13
114	Irinotecan-induced central nervous system toxicity: a case report. *Journal of the National Cancer Institute*, **1999**, 91, 647	9.7	13
113	The "El Alamo" project (1990-1997): two consecutive hospital-based studies of breast cancer outcomes in Spain. *Clinical and Translational Oncology*, **2006**, 8, 508-18	3.6	12
112	Health-related quality of life (HRQoL) of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with ribociclib + letrozole: Results from MONALEESA-2.. *Journal of Clinical Oncology*, **2017**, 35, 1020-1020	2.2	12
111	Targeted treatment approaches in refractory germ cell tumors. *Critical Reviews in Oncology/Hematology*, **2019**, 143, 130-138	7	11
110	Cross-sensitivity between taxanes in patients with breast cancer. *Clinical and Translational Oncology*, **2011**, 13, 904-6	3.6	11
109	Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM). *Clinical and Translational Oncology*, **2009**, 11, 363-75	3.6	11
108	Male breast cancer: immunohistochemical subtypes and clinical outcome characterization. *Oncology*, **2012**, 83, 228-33	3.6	11
107	Chemotherapy (CT) versus hormone therapy (HT) as neoadjuvant treatment in luminal breast cancer: A multicenter, randomized phase II study (GEICAM/2006-03).. *Journal of Clinical Oncology*, **2010**, 28, 500-500	2.2	11
106	Tumor histological subtyping determined by hormone receptors and HER2 status defines different pathological complete response and outcome to dose-dense neoadjuvant chemotherapy in breast cancer patients. *Clinical and Translational Oncology*, **2014**, 16, 548-54	3.6	10
105	A monolayer coagglutination microplate technique for typing red blood cells. *Vox Sanguinis*, **1997**, 72, 26-30	3.1	10
104	High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: a confirmatory prospective study. *Cancer*, **2007**, 110, 2178-85	6.4	10
103	Prognostic value of serum angiogenic activity in colorectal cancer patients. *Journal of Cellular and Molecular Medicine*, **2007**, 11, 120-8	5.6	10
102	A Neural Network Based Model for Prognosis of Early Breast Cancer. *Applied Intelligence*, **2004**, 20, 231-238	4.9	10
101	Role of vascular endothelial growth factor C in classical Hodgkin lymphoma. *Leukemia and Lymphoma*, **2015**, 56, 1286-94	1.9	9
100	Proliferation Determined by Ki-67 Defines Different Pathologic Response to Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer. *Clinical Breast Cancer*, **2015**, 15, 343-7	3	9
99	Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes. *Modern Pathology*, **2018**, 31, 299-306	9.8	9
98	Identification of genetic variants associated with capecitabine-induced hand-foot syndrome through integration of patient and cell line genomic analyses. *Pharmacogenetics and Genomics*, **2014**, 24, 231-7	1.9	9

97	Mapping the spatial distribution of entanglement in optical lattices. *Physical Review A*, **2010**, 82,	2.6	9
96	Presentation of Hodgkin's lymphoma with Ophelia syndrome. *Journal of Clinical Oncology*, **2007**, 25, 1802-3	2.3	9
95	Abstract CT045: Ribociclib + letrozole for first-line treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): efficacy by baseline tumor markers **2017**,		9
94	Critically short telomeres and toxicity of chemotherapy in early breast cancer. *Oncotarget*, **2017**, 8, 21472-21482	3.3	9
93	Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy. *Clinical and Translational Oncology*, **2018**, 20, 1548-1556	3.6	9
92	Sequential doxorubicin and docetaxel as first-line treatment in metastatic breast cancer: a GEICAM-9801 phase II study. *Breast Cancer Research and Treatment*, **2003**, 77, 1-8	4.4	8
91	Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile. *Current Cancer Drug Targets*, **2016**, 16, 415-28	2.8	8
90	Concurrent radiotherapy plus epidermal growth factor receptor inhibitors in patients with human papillomavirus-related head and neck cancer. *Clinical and Translational Oncology*, **2014**, 16, 418-24	3.6	7
89	Shift in the balance between circulating thrombospondin-1 and vascular endothelial growth factor in cancer patients: Relationship to platelet a-granule content and primary activation. *International Journal of Biological Markers*, **2004**, 19, 221-228	2.8	7
88	Inertial Sensors Embedded in Smartphones as a Tool for Fatigue Assessment Based on Acceleration in Survivors of Breast Cancer. *Physical Therapy*, **2020**, 100, 447-456	3.3	6
87	Effect of neuromuscular taping on musculoskeletal disorders secondary to the use of aromatase inhibitors in breast cancer survivors: a pragmatic randomised clinical trial. *BMC Complementary and Alternative Medicine*, **2018**, 18, 180	4.7	6
86	Functions and workload of medical oncologists in Spain. *Clinical and Translational Oncology*, **2012**, 14, 423-9	3.6	6
85	Outcome of small invasive breast cancer with no axillary lymph node involvement. *Breast Journal*, **2011**, 17, 32-8	1.2	6
84	Multimodal treatment of desmoid tumours: the significance of local control. *Clinical and Translational Oncology*, **2011**, 13, 189-93	3.6	6
83	Update on the diagnosis of cancer of unknown primary (CUP) origin. *Clinical and Translational Oncology*, **2011**, 13, 434-41	3.6	6
82	Optimal adjuvant hormonal therapy in postmenopausal women with hormone-receptor-positive early breast cancer: have we answered the question?. *Clinical and Translational Oncology*, **2010**, 12, 614-20	3.6	6
81	Cisplatin and intravenous continuous infusion of bleomycin in advanced and metastatic esophageal cancer. *European Journal of Cancer & Clinical Oncology*, **1988**, 24, 633-5		6
80	Early Breast Cancer Prognosis Prediction and Rule Extraction Using a New Constructive Neural Network Algorithm **2007**, 1004-1011		6

79	Significant Decrease in Annual Cancer Diagnoses in Spain during the COVID-19 Pandemic: A Real-Data Study. *Cancers*, **2021**, 13,	6.6	6
78	Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry). *Scientific Reports*, **2019**, 9, 20081	4.9	6
77	Cancer-related fatigue stratification system based on patient-reported outcomes and objective outcomes: A cancer-related fatigue ambulatory index. *PLoS ONE*, **2019**, 14, e0215662	3.7	5
76	Energy System Assessment in Survivors of Breast Cancer. *Physical Therapy*, **2020**, 100, 438-446	3.3	5
75	SEOM recommendations on the structure and operation of hereditary cancer genetic counseling units (HCGCUs). *Clinical and Translational Oncology*, **2013**, 15, 20-5	3.6	5
74	Second complete remission induced by cyclophosphamide plus bevacizumab in two patients with heavily pre-treated ovarian cancer. *Clinical and Translational Oncology*, **2009**, 11, 329-31	3.6	5
73	Prognosis of microinvasive breast carcinoma with negative axillary nodes in accordance with TNM classification criteria. *Breast Journal*, **2010**, 16, 669-71	1.2	5
72	ℚut of blueℚ ℚhermitteℚ sign: three cases due to low cumulative doses of oxaliplatin. *Annals of Oncology*, **2008**, 19, 2093-4	10.3	5
71	Treatment for relapse in stage I/II Hodgkinℚ lymphoma after initial single-modality treatment. *Clinical Lymphoma and Myeloma*, **2006**, 6, 389-92		5
70	Alternating chemotherapy for small-cell lung cancer. A twelve-week schedule of six drugs. *Annals of Oncology*, **1992**, 3, 31-5	10.3	5
69	Multicenter, randomized phase III study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles (cy) of FEC vs 4 cy of FEC followed by 8 weekly paclitaxel (T) administrations: Safety analysis of GEICAM 9906 trial. *Journal of Clinical Oncology*, **2004**, 22, 596-596	2.2	5
68	Subgroup analysis of GEICAM 9906 trial comparing six cycles of FE90C (FEC) to four cycles of FE90C followed by 8 weekly paclitaxel administrations (FECP): Relevance of HER2 and hormonal status (HR). *Journal of Clinical Oncology*, **2007**, 25, 10598-10598	2.2	5
67	The role of CDK4/6 inhibitors in early breast cancer. *Breast*, **2021**, 58, 160-169	3.6	5
66	Expression and Prognostic Value of Oestrogen Receptor Beta in Colorectal Cancer. *Pathology and Oncology Research*, **2018**, 24, 871-879	2.6	4
65	Hereditary breast and ovarian cancer in Andalusian families: a genetic population study. *BMC Cancer*, **2018**, 18, 647	4.8	4
64	Time to diagnosis of ewing tumors in children and adolescents is not associated with metastasis or survival. *Journal of Clinical Oncology*, **2014**, 32, 4020	2.2	4
63	Targeted therapies in the treatment of germ cell tumors: the need for new approaches against "orphan" tumors. *Critical Reviews in Oncology/Hematology*, **2012**, 83, 444-51	7	4
62	Proliferation determined by ki67 marker and pCR in locally advanced breast cancer patients treated with neo-adjuvant chemotherapy. *Breast Journal*, **2013**, 19, 685-6	1.2	4

61	Regional and seasonal influence in patient's toxicity to adjuvant chemotherapy for early breast cancer. *Breast Cancer Research and Treatment*, **2011**, 125, 273-8	4.4	4
60	First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-2 safety results.. *Journal of Clinical Oncology*, **2017**, 35, 1047-1047	2.2	4
59	Emerging noninvasive methylation biomarkers of cancer prognosis and drug response prediction. *Seminars in Cancer Biology*, **2021**,	12.7	4
58	Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data. *Frontiers in Oncology*, **2019**, 9, 1178	5.3	4
57	Machine learning and natural language processing (NLP) approach to predict early progression to first-line treatment in real-world hormone receptor-positive (HR+)/HER2-negative advanced breast cancer patients. *European Journal of Cancer*, **2021**, 144, 224-231	7.5	4
56	CT-Determined Sarcopenia in GLIM-Defined Malnutrition and Prediction of 6-Month Mortality in Cancer Inpatients. *Nutrients*, **2021**, 13,	6.7	4
55	Ocular side effects of checkpoint inhibitors. *Survey of Ophthalmology*, **2021**, 66, 951-959	6.1	4
54	A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer. *Frontiers in Oncology*, **2019**, 9, 303	5.3	3
53	Central sensitization in breast cancer survivors. *Journal of Applied Biobehavioral Research*, **2018**, 23, e12120	1.9	3
52	Supervised discretization can discover risk groups in cancer survival analysis. *Computer Methods and Programs in Biomedicine*, **2016**, 136, 11-9	6.9	3
51	P198 Prospective trans-GEICAM study of the impact of the 21-gene recurrence score assay and traditional clinico-pathological factors on clinical decision making in women with estrogen receptor-positive, HER2-negative, node-negative breast cancer. *Breast*, **2011**, 20, S43	3.6	3
50	Recomendación para la determinación de HER2 en cáncer de mama. Consenso nacional de la Sociedad Española de Anatomía Patológica (SEAP) y de la Sociedad Española de Oncología Médica (SEOM). *Revista Espanola De Patologia*, **2009**, 42, 3-16	1.2	3
49	Current controversies in the management of early breast cancer. *Clinical and Translational Oncology*, **2007**, 9, 375-84	3.6	3
48	Abstract P4-22-16: First-line ribociclib + letrozole in patients with HR+, HER2- advanced breast cancer (ABC) presenting with visceral metastases or bone-only disease: A subgroup analysis of the MONALEESA-2 trial **2017**,		3
47	Chemotherapy (CT) with or without carboplatin as neoadjuvant treatment in patients with basal-like breast cancer: GEICAM 2006-03. A multicenter, randomized phase II study.. *Journal of Clinical Oncology*, **2011**, 29, 1015-1015	2.2	3
46	Human papillomavirus (HPV)-related head and neck squamous cell carcinoma (HNSCC) and outcome after treatment with epidermal growth factor receptor inhibitors (EGFR inhib) plus radiotherapy (RT) versus conventional chemotherapy (CT) plus RT.. *Journal of Clinical Oncology*, **2011**, 29, 5528-5528	2.2	3
45	Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients.. *Journal of Clinical Oncology*, **2011**, 29, 5594-5594	2.2	3
44	Integrative cluster classification to predict pathological complete response to neoadjuvant chemotherapy in early breast cancer.. *Journal of Clinical Oncology*, **2018**, 36, 579-579	2.2	3

43	Cisplatin, 5-fluorouracil, and high-dose folinic acid in patients with advanced unresectable head and neck cancer. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **1996**, 19, 140-3	2.7	3
42	Winding number order in the Haldane model with interactions. *New Journal of Physics*, **2016**, 18, 033022	2.9	3
41	Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients. *Clinical and Translational Oncology*, **2009**, 11, 727-36	3.6	2
40	Current controversies in the management of breast cancer. *Clinical and Translational Oncology*, **2010**, 12, 278-86	3.6	2
39	Abstract P2-10-11: Prognostic performance of the EndoPredict score in node-positive chemotherapy-treated ER+/HER2 breast cancer patients: results from the GEICAM/9906 trial. **2012**,		2
38	Letrozole efficacy is related to human aromatase CYP19 single nucleotide polymorphisms (SNPs) in metastatic breast cancer patients. *Journal of Clinical Oncology*, **2004**, 22, 507-507	2.2	2
37	Spanish Breast Cancer Research Group (GEICAM) population-based study on breast cancer outcomes: El Álamo project (1990 1997). *Journal of Clinical Oncology*, **2005**, 23, 585-585	2.2	2
36	Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated recurrent ovarian cancer.. *Journal of Clinical Oncology*, **2010**, 28, e15507-e15507	2.2	2
35	Health-related quality of life of postmenopausal women with hormone receptor positive, HER2-advanced breast cancer treated with ribociclib + letrozole: Results from MONALEESA-2.. *Journal of Clinical Oncology*, **2017**, 35, 133-133	2.2	2
34	Pilot study on workload estimate in breast cancer, lung cancer and colorectal cancer in a Medical Oncology Service at Valme hospital. *Clinical and Translational Oncology*, **2012**, 14, 820-6	3.6	1
33	Antiangiogenic therapy of breast cancer: how did we get here?: the road not taken. *Clinical and Translational Oncology*, **2011**, 13, 765-6	3.6	1
32	Time-to-progression in breast cancer: a stratification model for clinical trials. *Breast*, **2008**, 17, 239-44	3.6	1
31	Diagnosis and medical treatment of breast cancer. Cordoba Consensus of 2007. *Clinical and Translational Oncology*, **2008**, 10, 552-9	3.6	1
30	Weekly First-Line Chemotherapy of Metastatic Breast Cancer with Cyclophosphamide and Epirubicin. *Tumori*, **1992**, 78, 338-340	1.7	1
29	Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer.. *Frontiers in Oncology*, **2021**, 11, 827625	5.3	1
28	Phase I study of high-dose bi-weekly gemcitabine at a constant rate infusion (CRI) without growth factor support in advanced solid tumors, including prior standard gemcitabine treated patients. *Journal of Clinical Oncology*, **2005**, 23, 2067-2067	2.2	1
27	Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes.. *Journal of Clinical Oncology*, **2016**, 34, 1585-1585	2.2	1
26	Resistance to Neoadjuvant Treatment in Breast Cancer: Clinicopathological and Molecular Predictors. *Cancers*, **2020**, 12,	6.6	1

25	Structural validity and reliability of the Spanish Central Sensitization Inventory in breast cancer survivors. *Pain Practice*, **2021**, 21, 740-746	3	1
24	Advanced Online Survival Analysis Tool for Predictive Modelling in Clinical Data Science. *PLoS ONE*, **2016**, 11, e0161135	3.7	1
23	Ability of final PET/CT to predict response to first-line treatment in real patients with classical Hodgkin lymphoma. *International Journal of Hematology*, **2021**, 1	2.3	1
22	Effectiveness of an individualized program of muscular strength and endurance with aerobic training for improving germ cell cancer-related fatigue in men undergoing chemotherapy: EFICATEST study protocol for a randomized controlled trial. *Trials*, **2016**, 17, 8	2.8	0
21	Subcellular localisation of pMEK has a different prognosis in locally advanced head and neck cancer treated with concomitant radiochemotherapy. *BMC Cancer*, **2016**, 16, 829	4.8	0
20	Regulatory CDH4 Genetic Variants Associate With Risk to Develop Capecitabine-Induced Hand-Foot Syndrome. *Clinical Pharmacology and Therapeutics*, **2021**, 109, 462-470	6.1	0
19	Design and implementation of a standard care programme of therapeutic exercise and education for breast cancer survivors. *Supportive Care in Cancer*, **2021**, 1	3.9	0
18	Development of a functional assessment task in metastatic breast cancer patients: the 30-second lie-to-sit test. *Disability and Rehabilitation*,1-8	2.4	0
17	Grado de acuerdo entre la acelerometría y el Cuestionario Internacional de Actividad Física en pacientes supervivientes de cáncer de mama. *Fisioterapia*, **2018**, 40, 26-35	0.2	
16	18F-FDG-PET/CT in predicting pathologic complete response after neoadjuvant chemotherapy: the early metabolic response is the answer. *European Journal of Cancer*, **2013**, 49, 3573-4	7.5	
15	Adjuvant high-dose interferon therapy for melanoma: nothing has really changed. *Melanoma Research*, **2014**, 24, 522-3	3.3	
14	Practical guidelines for dose individualization of anticancer targeted drugs. *Clinical and Translational Oncology*, **2012**, 14, 812-9	3.6	
13	Bevacizumab in advanced breast cancer: a new model for the assessment of activity in non-first-line treatment regimens. *Anti-Cancer Drugs*, **2013**, 24, 975-9	2.4	
12	Aromatase inhibitors as adjuvant therapy for breast cancer: overall survival versus disease-free survival as a primary end point in clinical practice. *Journal of Clinical Oncology*, **2009**, 27, e255-6; author reply e257-8	2.2	
11	An uncommon presentation of non-Hodgkin's lymphoma: diffuse large-cell lymphoma presenting as a peritoneal mass. *Leukemia and Lymphoma*, **2006**, 47, 933-4	1.9	
10	Variabilidad en la utilización del tratamiento conservador del cancer de marna localizado en un área geográfica **2000**, 2, 202-206		
9	Prognostic value of immunohistochemical phenotypes (IP) of 141 operable breast cancer patients (pts) included in phase III trials of adjuvant therapy. *Journal of Clinical Oncology*, **2007**, 25, 21040-21040	2.2	
8	Plasma sequencing of ctDNA in early stage breast cancer as part of the screening process.. *Journal of Clinical Oncology*, **2018**, 36, 12073-12073	2.2	

LIST OF PUBLICATIONS

7	Dynamic genomic instability modulation by neoadjuvant therapy in early breast cancer (GEICAM/2006-03_2006-14).. *Journal of Clinical Oncology*, **2018**, 36, 592-592	2.2
6	Contribution of trastuzumab to the prognostic improvement of HER2-positive early breast cancer in Spain: an estimation of life years and disease-free life years gained since its approval. *Oncotarget*, **2019**, 10, 4321-4332	3.3
5	Triple-negative breast cancer subtypes and pathologic complete-response rate to neoadjuvant chemotherapy: Results from the GEICAM/2006-2003 study.. *Journal of Clinical Oncology*, **2014**, 32, 1024-1024	2.2
4	Blinded independent validation of the PAM50-based Chemo-Endocrine Sensitivity Predictor (CESP) in hormone receptor (HR)-positive/HER2-negative (HR+/HER2-) breast cancer following neoadjuvant chemotherapy (NAC).. *Journal of Clinical Oncology*, **2015**, 33, 569-569	2.2
3	Outcomes of single versus double hormone receptor positive breast cancer.. *Journal of Clinical Oncology*, **2016**, 34, 569-569	2.2
2	Optimization of oral chemotherapy in outpatient clinics in Spain: results from a survey of the Spanish Society of Medical Oncology (SEOM). *Clinical and Translational Oncology*, **2019**, 21, 534-538	3.6
1	Abstract P4-07-10: Patient profiles, management and treatment patterns in HR+, HER2- early breast cancer in a real-world setting in Spain. *Cancer Research*, **2022**, 82, P4-07-10-P4-07-10	10.1